Redefining the Scalpel: Past, Present, and Future Perspectives on the Surgical Management of Pancreatic Ductal Adenocarcinoma (PDAC)
DOI:
https://doi.org/10.59928/6vdnww93Abstract
PDAC is still one of the most lethal cancer challenges, since it is characterized by an aggressive biology, early systemic dissemination, and a historically dismal prognosis. For many years, surgical resection has been considered the only potential treatment modality. However, the role, performance, extent, and opportunity of pancreatectomy (either distal or pancreatoduodenectomy) have undergone a significant paradigm shift. This manuscript traces the evolution of PDAC surgery from its dawn to a highly standardized procedure in high-volume centers. In the current era, the therapeutic paradigm has predominantly shifted from a “surgery-first” approach to an aggressive multidisciplinary approach, where advanced systemic neoadjuvant regimens and minimally invasive (laparoscopic/robotic) approaches are systematically used to achieve R0 resection. The future will likely overcome macro- and micro-anatomical boundaries through the full integration of artificial intelligence (AI), radiomics, molecular margin assessment, intraoperative navigation, and personalized immunotherapies. In that fashion, the pancreatic surgeon will need to transition from technician to biological oncologist, and his/her scalpel will transform into a bridge toward systemic disease eradication. Key Points • Question: How has the role of surgical resection for PDAC evolved through different stages and landscapes? • Findings: The field has shifted from high mortality and few resections to safer, mostly centralized interventions. Neoadjuvant therapy, vascular resections, and minimally invasive (laparoscopic and robotic) platforms characterize the present. The future will integrate artificial intelligence-aided resources, real-time fluorescence-guided molecular margins, and personalized post-operative mRNA vaccines. • Meaning: surgical management of PDAC has shifted from a focus on macro-anatomical technical feasibility to a biology-driven, technologically integrated component of personalized oncologic treatment.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 The Author(s)

This work is licensed under a Creative Commons Attribution 4.0 International License.